Boston to acquire Remon
This article was originally published in Clinica
Executive Summary
Boston Scientific is set to acquire Israeli wireless technology specialist Remon Medical Technologies. The deal, which is expected to close by the end of the third quarter, will combine Remon's miniature intra-body monitoring implants with Boston's cardiac rhythm management product line, in a bid to boost post-operative monitoring, nerve and tissue stimulation, local drug delivery, and drug development. Remon houses the RemonCHF (congestive heart failure) monitoring system for looking at patients' hemodynamic status, and the RemonAAA (abdominal aortic aneurysm) post-operative monitoring system for examining pressure, following an endograft procedure. Details of the acquisition were not disclosed.